Biomarker Testing Falls Short in NSCLC

Area of Science:

• Oncology
• Medical Diagnostics
• Public Health

Background:

• Biomarker testing is critical for guiding targeted therapy in non-small cell lung cancer (NSCLC).
• Current clinical practice reveals significant gaps in the routine application of biomarker testing for NSCLC patients.
• Two recent studies highlight deficiencies in diagnostic testing rates prior to treatment initiation.

Discussion:

• A substantial proportion of NSCLC patients do not receive recommended biomarker testing before commencing therapy.
• Disparities in testing rates exist, with African American patients showing lower rates of biomarker testing and next-generation sequencing compared to white patients.
• These findings underscore potential inequities in accessing precision medicine for lung cancer.

Key Insights:

• Over 20% of NSCLC patients are not tested for biomarkers prior to treatment.
• African Americans with NSCLC experience lower biomarker testing rates (3% less) and next-generation sequencing rates (10% less) than white patients.
• Inadequate testing limits the potential for personalized treatment strategies in lung cancer.

Outlook:

• There is a critical need to improve biomarker testing rates and address racial disparities in NSCLC care.
• Implementing standardized testing protocols and targeted interventions can enhance equitable access to precision oncology.
• Future research should focus on identifying barriers to testing and evaluating the impact of improved testing on patient outcomes.